GetTopicDetailResponse(id=d4c513e6337, topicName=PARP抑制劑Niraparib, introduction=PARP抑制劑Niraparib, content=null, image=null, comments=3, allHits=1208, url=https://h5.medsci.cn/topic?id=13763, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=102680, tagList=[TagDto(tagId=102680, tagName=PARP抑制劑Niraparib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1715628, encodeId=5e311e15628f4, content=<a href='/topic/show?id=d4c513e6337' target=_blank style='color:#2F92EE;'>#PARP抑制劑Niraparib#</a>, objectTitle=再鼎醫(yī)藥的PARP抑制劑Niraparib用于卵巢癌維持治療，獲得NMPA授予優(yōu)先審查, objectType=article, longId=192482, objectId=1c3c1924827f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c3c1924827f, replyNumber=0, likeNumber=95, createdTime=2020-06-28, rootId=0, userName=ms1260584454294838, userId=d54031982059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c3c1924827f, moduleTitle=再鼎醫(yī)藥的PARP抑制劑Niraparib用于卵巢癌維持治療，獲得NMPA授予優(yōu)先審查, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1c3c1924827f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715627, encodeId=34591e156275a, content=<a href='/topic/show?id=d4c513e6337' target=_blank style='color:#2F92EE;'>#PARP抑制劑Niraparib#</a>, objectTitle=2019 ESMO：PARP抑制劑Niraparib可顯著提高化療成功的晚期卵巢癌患者無進展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=99, createdTime=2020-02-20, rootId=0, userName=ms1260584454294838, userId=d54031982059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制劑Niraparib可顯著提高化療成功的晚期卵巢癌患者無進展生存期, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1715626, encodeId=3ce41e15626df, content=<a href='/topic/show?id=d4c513e6337' target=_blank style='color:#2F92EE;'>#PARP抑制劑Niraparib#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制劑Niraparib治療轉(zhuǎn)移性去勢抵抗性前列腺癌的突破性療法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=80, createdTime=2019-12-31, rootId=0, userName=ms1260584454294838, userId=d54031982059, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制劑Niraparib治療轉(zhuǎn)移性去勢抵抗性前列腺癌的突破性療法指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
